Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm
Comparision of Safety and Efficacy Between Modified Double Snare Assisted EMR (mDS-EMR) and ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm: a Prospective Non-inferiority Randomized Controlled Study
2 other identifiers
interventional
118
0 countries
N/A
Brief Summary
The aim of this study is evaluating and safety and efficacy between the modified double snare EMR and ESD. It is intended to prove that for rectal neuroendocrine tumors within 1 cm, the complete resection rate of the mDS-EMR is not inferior to that of ESD, but may with shorter operation time, lower complication rate and lower treatment cost.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2026
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2026
CompletedFirst Submitted
Initial submission to the registry
January 9, 2026
CompletedFirst Posted
Study publicly available on registry
January 28, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2028
January 28, 2026
December 1, 2025
2.4 years
January 9, 2026
January 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
complete resection
Rate of complete en bloc resection with microscopically negative margins.
Day 30
Secondary Outcomes (6)
En bloc resection
Day 30
operation success rate
Periprocedural
operation time
Periprocedural
Postoperative hospital stay
through study completion, an average of 30 days
operation-related expenses
through study completion, an average of 30 days
- +1 more secondary outcomes
Other Outcomes (4)
Delayed perforation
30 days after the operation
Delayed bleeding
30 days after the operation
Intraoperative bleeding
Intraoperative
- +1 more other outcomes
Study Arms (2)
ESD
ACTIVE COMPARATORThe traditional ESD treatment method is adopted, which includes submucosal injection of normal saline and methylene blue suspension, cutting and dissection by mucosal incision knife, hemostasis and cliping of the wound. Traction is allowed during the operation.
mDS-EMR
EXPERIMENTALModified double snare assisted EMR was used for treatment. Put the first snare for resecting outside the endoscope body. Then put the second snare at the base through the channel to tighten the lesion. Finally, place the first snare below the second one to tighten the lesion and perform electrically-assisted removal. Then, metal clips will be used to close the wound.
Interventions
A polypectomy snare (resection snare) was placed outside of the endoscope. After approaching the lesion, a second polypectomy snare (capture snare) was inserted through the biopsy channel of the endoscope to grasp and lift the lesion. The snare preloaded outside of the endoscope was released, passed through the capture snare and positioned below the capture snare to grasp the base of the lesion. Once the lesion was securely grasped, it was resected by resection snare to achieve en bloc resection. The wounds were closed by clips.
The procedure includes submucosal injection of normal saline and methylene blue suspension, cutting and dissection by mucosal incision knife (such as Dual knife, Golden knife or Kunpeng knife, etc.) , hemostasis and sealing of the wound. Traction is allowed during the operation.
Eligibility Criteria
You may qualify if:
- Typical rectal neuroendocrine tumors by endoscopy (within 15cm from the anal verge, yellowish subepithelial elevation with a smooth surface, and dilated blood vessels in some areas).
- The maximum diameter of the lesion is smaller than 1cm by preoperative endoscopic assessment.
- Lesion is located within the mucosal and submucosal layer by preoperative endoscopic assessment.
- Patients can understand and sign the informed consent.
You may not qualify if:
- Poor coagulation function(PT\>15 seconds or APTT\>45 seconds or INR\>2.0)
- With severe cardiovascular or cerebrovascular diseases and cannot tolerate operation( with a history of stroke or myocardial infarction within the past month or with severe heart failure and cardiac function grade III)
- Indication of metastasis by preoperative imaging examinations
- With more than or equal to 2 rectal neuroendocrine tumors
- With other complications that are not suitable for this study by multidisciplinary team assesment
- Cases of recurrence after operation for neuroendocrine tumors
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 9, 2026
First Posted
January 28, 2026
Study Start
January 1, 2026
Primary Completion (Estimated)
May 31, 2028
Study Completion (Estimated)
June 30, 2028
Last Updated
January 28, 2026
Record last verified: 2025-12